Increased Hepatic ACE2 Expression in NAFL and Diabetes—A Risk for COVID-19 Patients?
- 11 September 2020
- journal article
- letter
- Published by American Diabetes Association in Diabetes Care
- Vol. 43 (10), e134-e136
- https://doi.org/10.2337/dc20-1458
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- Transmission of SARS-CoV-2 in Domestic CatsThe New England Journal of Medicine, 2020
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City AreaJAMA, 2020
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike GlycoproteinCell, 2020
- Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV InfectionPublished by Cold Spring Harbor Laboratory ,2020